NASDAQ:NVAX - Novavax Stock Price, Price Target & More

$1.71 -0.01 (-0.58 %)
(As of 04/23/2018 01:40 AM ET)
Previous Close$1.71
Today's Range$1.71 - $1.7550
52-Week Range$0.73 - $2.75
Volume4.93 million shs
Average Volume7.47 million shs
Market Capitalization$652.53 million
P/E Ratio-2.71
Dividend YieldN/A
Beta2.38

About Novavax (NASDAQ:NVAX)

Novavax logoNovavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000

Debt

Debt-to-Equity Ratio-3.12%
Current Ratio2.76%
Quick Ratio2.76%

Price-To-Earnings

Trailing P/E Ratio-2.71
Forward P/E Ratio-3.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$31.18 million
Price / Sales20.93
Cash FlowN/A
Price / CashN/A
Book Value($0.31) per share
Price / Book-5.52

Profitability

EPS (Most Recent Fiscal Year)($0.63)
Net Income$-183,760,000.00
Net Margins-589.46%
Return on EquityN/A
Return on Assets-54.30%

Miscellaneous

Employees347
Outstanding Shares381,600,000

How to Become a New Pot Stock Millionaire

Novavax (NASDAQ:NVAX) Frequently Asked Questions

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How were Novavax's earnings last quarter?

Novavax (NASDAQ:NVAX) issued its earnings results on Wednesday, March, 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.01. The biopharmaceutical company had revenue of $10.40 million for the quarter, compared to analyst estimates of $7.98 million. The business's revenue for the quarter was up 92.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.21) earnings per share. View Novavax's Earnings History.

What price target have analysts set for NVAX?

8 equities research analysts have issued 12-month target prices for Novavax's stock. Their predictions range from $1.35 to $10.00. On average, they anticipate Novavax's share price to reach $3.5125 in the next year. View Analyst Ratings for Novavax.

What are Wall Street analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:
  • 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (4/11/2018)
  • 2. Cantor Fitzgerald analysts commented, "NanoFlu seasonal flu vaccine could be just what the Dr. ordered. The mismatch of commercially available (egg-production-based) seasonal flu vaccines in the current season underscores the theoretical utility of NVAX’s vaccine production technology. Avoiding influenza virus propagation in eggs could reduce the need for egg adaptation and possible generation of virus particles that do not faithfully resemble the wild type viruses recommended by health organizations for inclusion in flu vaccines. Particularly when prevailing strains are highly pathogenic, e.g., H3N2, having a better matched flu vaccine would seem to be desirable, in our view." (3/15/2018)

Are investors shorting Novavax?

Novavax saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 56,065,847 shares, an increase of 10.1% from the March 15th total of 50,911,520 shares. Based on an average trading volume of 8,148,869 shares, the days-to-cover ratio is presently 6.9 days. Currently, 17.6% of the shares of the company are short sold.

Who are some of Novavax's key competitors?

Who are Novavax's key executives?

Novavax's management team includes the folowing people:
  • Mr. Stanley Charles Erck, Pres, CEO, Interim CFO, Principal Accounting Officer & Director (Age 70)
  • Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 52)
  • Mr. John Joseph Trizzino B.S., M.B.A., Sr. VP of Commercial Operations (Age 58)
  • Dr. Gregory M. Glenn M.D., Pres of R&D (Age 64)
  • Ms. Jill Hoyt, VP of HR & Admin.

Has Novavax been receiving favorable news coverage?

Media stories about NVAX stock have been trending somewhat positive recently, Accern reports. The research firm scores the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novavax earned a media sentiment score of 0.05 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.85 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $1.71.

How big of a company is Novavax?

Novavax has a market capitalization of $652.53 million and generates $31.18 million in revenue each year. The biopharmaceutical company earns $-183,760,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Novavax employs 347 workers across the globe.

How can I contact Novavax?

Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]


MarketBeat Community Rating for Novavax (NVAX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  549
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novavax (NASDAQ:NVAX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Novavax in the last 12 months. Their average twelve-month price target is $3.5125, suggesting that the stock has a possible upside of 105.41%. The high price target for NVAX is $10.00 and the low price target for NVAX is $1.35. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.382.252.292.25
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.5125$3.3714$2.8357$3.35
Price Target Upside: 105.41% upside56.08% upside33.76% upside188.79% upside

Novavax (NASDAQ:NVAX) Consensus Price Target History

Price Target History for Novavax (NASDAQ:NVAX)

Novavax (NASDAQ:NVAX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018Piper JaffrayLower Price TargetNeutral$2.00MediumView Rating Details
3/29/2018B. RileyReiterated RatingBuyHighView Rating Details
3/29/2018Seaport Global SecuritiesUpgradeNeutral -> Buy$5.00HighView Rating Details
3/19/2018JPMorgan ChaseDowngradeNeutral -> UnderweightMediumView Rating Details
3/15/2018Cantor FitzgeraldReiterated RatingHold$2.00MediumView Rating Details
3/1/2018Chardan CapitalReiterated RatingHoldHighView Rating Details
3/1/2018CitigroupUpgradeNeutral -> BuyHighView Rating Details
3/1/2018Ladenburg ThalmannReiterated RatingBuy$3.50HighView Rating Details
1/10/2018S&P Equity ResearchLower Price Target$1.81 -> $1.35HighView Rating Details
1/18/2017FBR & CoReiterated RatingOutperform$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$2.00 -> $1.50N/AView Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Novavax (NASDAQ:NVAX) Earnings History and Estimates Chart

Earnings by Quarter for Novavax (NASDAQ:NVAX)

Novavax (NASDAQ:NVAX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.55)
2019 EPS Consensus Estimate: ($0.62)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20182($0.15)($0.14)($0.15)
Q3 20183($0.16)($0.10)($0.13)
Q4 20183($0.16)($0.13)($0.14)
Q1 20191($0.14)($0.14)($0.14)
Q2 20191($0.15)($0.15)($0.15)
Q3 20191($0.16)($0.16)($0.16)
Q4 20191($0.17)($0.17)($0.17)

Novavax (NASDAQ NVAX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018Q4 17($0.15)($0.16)$7.98 million$10.40 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.16)($0.15)$6.42 million$8.35 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.16)($0.16)$6.15 million$6.70 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.18)($0.16)$6.17 million$5.68 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.21)$5.45 million$5.40 millionViewListenView Earnings Details
11/9/2016Q316($0.26)($0.24)$4.02 million$3.20 millionViewListenView Earnings Details
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
11/5/2010Q3 2010($0.09)($0.10)ViewN/AView Earnings Details
8/6/2010Q2 2010($0.10)($0.09)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.13)($0.11)ViewN/AView Earnings Details
3/12/2010Q4 2009($0.04)($0.15)ViewN/AView Earnings Details
11/6/2009Q3 2009($0.09)($0.08)ViewN/AView Earnings Details
8/7/2009Q2 2009($0.11)($0.10)ViewN/AView Earnings Details
5/8/2009Q1 2009($0.12)($0.12)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.13)($0.11)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.14)($0.16)ViewN/AView Earnings Details
8/8/2008Q2 2008($0.14)($0.14)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.12)($0.12)ViewN/AView Earnings Details
3/14/2008Q4 2007($0.13)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Novavax (NASDAQ:NVAX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Novavax (NASDAQ NVAX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 36.88%
Insider Trading History for Novavax (NASDAQ:NVAX)
Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Novavax (NASDAQ NVAX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2018Gregory M. GlennInsiderBuy12,784$0.88$11,249.92View SEC Filing  
11/9/2017Stanley C ErckInsiderBuy100,000$1.13$113,000.00228,279View SEC Filing  
8/31/2017James F. YoungDirectorSell175,000$1.06$185,500.00View SEC Filing  
7/31/2017Barclay A. PhillipsCFOBuy2,057$0.89$1,830.73View SEC Filing  
5/12/2017Michael A Mcmanus JrDirectorBuy20,000$0.97$19,400.00277,590View SEC Filing  
5/11/2017Barclay A PhillipsCFOBuy25,000$0.84$21,000.0036,612View SEC Filing  
5/11/2017Michael A Mcmanus JrDirectorBuy10,000$0.84$8,400.00257,590View SEC Filing  
5/11/2017Stanley C ErckInsiderBuy50,000$0.84$42,000.00128,279View SEC Filing  
1/31/2017Barclay A. PhillipsCFOBuy1,633$1.12$1,828.96View SEC Filing  
1/31/2017John A. Herrmann IIISVPBuy4,960$1.12$5,555.20View SEC Filing  
12/7/2016Gregory M GlennInsiderBuy1,000$1.45$1,450.004,427View SEC Filing  
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.0085,564View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.003,427View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00247,590View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00200,000View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00321,979View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00357,111View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82301,066View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.8040View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00340,977View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.369,152View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.001,158View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.0014,868View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00250,000View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.0084,868View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.729,868View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.7274,868View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.6480,416View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novavax (NASDAQ NVAX) News Headlines

Source:
DateHeadline
Q2 2018 Earnings Estimate for Novavax Issued By Piper Jaffray (NVAX)Q2 2018 Earnings Estimate for Novavax Issued By Piper Jaffray (NVAX)
www.americanbankingnews.com - April 19 at 6:26 AM
Free Research Reports on These Biotech Stocks -- Moleculin Biotech, MyoKardia, Nektar Therapeutics, and NovavaxFree Research Reports on These Biotech Stocks -- Moleculin Biotech, MyoKardia, Nektar Therapeutics, and Novavax
www.prnewswire.com - April 18 at 8:44 AM
Novavax (NVAX) Downgraded by BidaskClub to "Sell"Novavax (NVAX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 17 at 1:54 PM
Novavax (NVAX) Price Target Lowered to $2.00 at Piper JaffrayNovavax (NVAX) Price Target Lowered to $2.00 at Piper Jaffray
www.americanbankingnews.com - April 17 at 8:27 AM
Buy Novavax After Its Latest Pullback?Buy Novavax After Its Latest Pullback?
finance.yahoo.com - April 17 at 8:25 AM
Novavax Announces Closing of Public OfferingNovavax Announces Closing of Public Offering
finance.yahoo.com - April 16 at 5:29 PM
Piper Jaffray Reiterates "Hold" Rating for Novavax (NVAX)Piper Jaffray Reiterates "Hold" Rating for Novavax (NVAX)
www.americanbankingnews.com - April 15 at 11:42 PM
Novavax (NVAX) Lowered to Hold at Zacks Investment ResearchNovavax (NVAX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 15 at 11:11 PM
Novavax (NVAX) Earns Neutral Rating from Chardan CapitalNovavax (NVAX) Earns Neutral Rating from Chardan Capital
www.americanbankingnews.com - April 15 at 2:21 PM
Novavax (NVAX) Upgraded by BidaskClub to HoldNovavax (NVAX) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - April 15 at 12:35 PM
Novavax, Inc.Novavax, Inc.
www.streetinsider.com - April 13 at 5:26 PM
Today’s Research Reports on Stocks to Watch: Novavax and PfizerToday’s Research Reports on Stocks to Watch: Novavax and Pfizer
finance.yahoo.com - April 13 at 8:32 AM
Heres Why Novavax, Inc. Is SinkingHere's Why Novavax, Inc. Is Sinking
www.fool.com - April 12 at 5:29 PM
Here's Why Novavax, Inc. Is SinkingHere's Why Novavax, Inc. Is Sinking
finance.yahoo.com - April 12 at 5:29 PM
Novavaxs stock plunges on heavy volume after public offering prices at deep discountNovavax's stock plunges on heavy volume after public offering prices at deep discount
finance.yahoo.com - April 12 at 5:29 PM
Novavax Pulls The Trigger On A Stock Offering: What Now?Novavax Pulls The Trigger On A Stock Offering: What Now?
seekingalpha.com - April 12 at 8:44 AM
Novavax (NVAX) Short Interest UpdateNovavax (NVAX) Short Interest Update
www.americanbankingnews.com - April 12 at 1:09 AM
Novavax -11.1% on report of 25M-share offering at $1.65Novavax -11.1% on report of 25M-share offering at $1.65
seekingalpha.com - April 11 at 7:28 PM
Novavax Announces Proposed Public Offering of Common StockNovavax Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 11 at 5:26 PM
Novavax (NVAX) Upgraded by Zacks Investment Research to BuyNovavax (NVAX) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 11 at 9:21 AM
BidaskClub Upgrades Novavax (NVAX) to "Hold"BidaskClub Upgrades Novavax (NVAX) to "Hold"
www.americanbankingnews.com - April 10 at 3:28 PM
Novavax (NVAX) Upgraded by Zacks Investment Research to "Buy"Novavax (NVAX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 10 at 9:44 AM
$8.83 Million in Sales Expected for Novavax (NVAX) This Quarter$8.83 Million in Sales Expected for Novavax (NVAX) This Quarter
www.americanbankingnews.com - April 9 at 4:41 AM
UPDATE: JPMorgan Downgrades Novavax (NVAX) to UnderweightUPDATE: JPMorgan Downgrades Novavax (NVAX) to Underweight
www.streetinsider.com - April 8 at 9:05 AM
Zacks: Brokerages Expect Novavax (NVAX) Will Announce Earnings of -$0.14 Per ShareZacks: Brokerages Expect Novavax (NVAX) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 7 at 1:15 AM
Pick 3 Biotech Money-Spinning Bets Amid Market InstabilityPick 3 Biotech Money-Spinning Bets Amid Market Instability
finance.yahoo.com - April 6 at 5:25 PM
Novavax (NVAX) Downgraded by Zacks Investment ResearchNovavax (NVAX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:34 AM
Novavax (NVAX) Given Average Recommendation of "Hold" by BrokeragesNovavax (NVAX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 3:40 PM
3 Top Small-Cap Biotech Stocks for Aggressive Investors3 Top Small-Cap Biotech Stocks for Aggressive Investors
finance.yahoo.com - April 3 at 8:13 AM
Novavax (NVAX) Upgraded at Zacks Investment ResearchNovavax (NVAX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 3 at 7:49 AM
Novavaxs (NVAX) "Buy" Rating Reiterated at B. RileyNovavax's (NVAX) "Buy" Rating Reiterated at B. Riley
www.americanbankingnews.com - April 3 at 7:48 AM
Novavax (NVAX) Raised to "Buy" at CitigroupNovavax (NVAX) Raised to "Buy" at Citigroup
www.americanbankingnews.com - April 2 at 9:42 PM
Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine CongressNovavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress
www.globenewswire.com - April 2 at 9:14 AM
Novavax to Present Clinical Data on RSV F and NanoFlu(TM) Vaccines at World Vaccine CongressNovavax to Present Clinical Data on RSV F and NanoFlu(TM) Vaccines at World Vaccine Congress
finance.yahoo.com - April 2 at 9:14 AM
Seaport Global Securities Weighs in on Novavaxs Q1 2018 Earnings (NVAX)Seaport Global Securities Weighs in on Novavax's Q1 2018 Earnings (NVAX)
www.americanbankingnews.com - March 30 at 6:52 AM
Analysts’ Ratings for Sorrento and Its Peers in March 2018Analysts’ Ratings for Sorrento and Its Peers in March 2018
finance.yahoo.com - March 29 at 5:16 PM
What Analysts Recommend for AbbVie and Peers in March 2018What Analysts Recommend for AbbVie and Peers in March 2018
finance.yahoo.com - March 29 at 5:16 PM
Seaport Global Securities Upgrades Novavax (NVAX) to BuySeaport Global Securities Upgrades Novavax (NVAX) to Buy
www.americanbankingnews.com - March 29 at 12:12 PM
Novavax (NVAX) Cut to "Hold" at Zacks Investment ResearchNovavax (NVAX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 10:58 AM
Novavax (NVAX) Raised to "Buy" at Zacks Investment ResearchNovavax (NVAX) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 28 at 10:26 AM
Forget Merck: Novavax, Inc. Is a Better Vaccine StockForget Merck: Novavax, Inc. Is a Better Vaccine Stock
finance.yahoo.com - March 28 at 8:01 AM
Short Interest in Novavax (NVAX) Expands By 4.7%Short Interest in Novavax (NVAX) Expands By 4.7%
www.americanbankingnews.com - March 28 at 2:02 AM
Novavax (NVAX) PT Set at $10.00 by B. RileyNovavax (NVAX) PT Set at $10.00 by B. Riley
www.americanbankingnews.com - March 24 at 2:45 PM
Ladenburg Thalmann Financial Services Reaffirms "Buy" Rating for Novavax (NVAX)Ladenburg Thalmann Financial Services Reaffirms "Buy" Rating for Novavax (NVAX)
www.americanbankingnews.com - March 24 at 1:56 PM
Novavax (NVAX) Stock Rating Lowered by Zacks Investment ResearchNovavax (NVAX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 23 at 9:34 PM
When Will Novavax Inc (NASDAQ:NVAX) Become Profitable?When Will Novavax Inc (NASDAQ:NVAX) Become Profitable?
finance.yahoo.com - March 23 at 6:07 PM
Novavax, Inc. to Post FY2018 Earnings of ($0.83) Per Share, Cantor Fitzgerald Forecasts (NVAX)Novavax, Inc. to Post FY2018 Earnings of ($0.83) Per Share, Cantor Fitzgerald Forecasts (NVAX)
www.americanbankingnews.com - March 23 at 10:38 AM
 Analysts Expect Novavax, Inc. (NVAX) Will Post Quarterly Sales of $9.60 Million Analysts Expect Novavax, Inc. (NVAX) Will Post Quarterly Sales of $9.60 Million
www.americanbankingnews.com - March 23 at 9:36 AM
Novavax, Inc. Forecasted to Post FY2019 Earnings of ($0.58) Per Share (NVAX)Novavax, Inc. Forecasted to Post FY2019 Earnings of ($0.58) Per Share (NVAX)
www.americanbankingnews.com - March 22 at 3:17 PM
Novavax: New RSV Vaccine Timeline Raises Cash Concerns - Seeking AlphaNovavax: New RSV Vaccine Timeline Raises Cash Concerns - Seeking Alpha
seekingalpha.com - March 22 at 8:25 AM

SEC Filings

Novavax (NASDAQ:NVAX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novavax (NASDAQ:NVAX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novavax (NASDAQ NVAX) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.